Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 3,916,000 | 1,548,000 | 1,993,000 | 2,227,000 | 3,552,000 |
| Depreciation Amortization | 3,149,000 | 3,762,000 | 3,753,000 | 3,036,000 | 2,357,000 |
| Accounts receivable | -739,000 | -898,000 | -523,000 | 83,000 | 1,610,000 |
| Accounts payable and accrued liabilities | 1,721,000 | 868,000 | -103,000 | 415,000 | -341,000 |
| Other Working Capital | 361,000 | -346,000 | -639,000 | -50,000 | 926,000 |
| Other Operating Activity | -3,609,000 | -1,965,000 | -1,863,000 | -2,133,000 | -3,959,000 |
| Operating Cash Flow | $4,799,000 | $2,969,000 | $2,618,000 | $3,578,000 | $4,145,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 745,000 | 194,000 | 405,000 | -345,000 | -166,000 |
| PPE Investments | -855,000 | -942,000 | -1,031,000 | -1,243,000 | -1,364,000 |
| Net Acquisitions | -822,000 | -709,000 | -349,000 | -1,450,000 | -2,564,000 |
| Purchase Of Investment | -119,000 | -13,000 | -102,000 | -96,000 | -230,000 |
| Sale Of Investment | 1,381,000 | 18,000 | 24,000 | 70,000 | 3,000 |
| Purchase Sale Intangibles | -694,000 | 595,000 | 2,010,000 | 1,082,000 | 559,000 |
| Other Investing Activity | -615,000 | 795,000 | 2,016,000 | 736,000 | 352,000 |
| Investing Cash Flow | $-285,000 | $-657,000 | $963,000 | $-2,328,000 | $-3,969,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 288,000 | -516,000 | -98,000 | 336,000 | -303,000 |
| Debt Issued | 2,968,000 | 500,000 | 2,971,000 | 1,988,000 | 2,491,000 |
| Debt Repayment | -1,609,000 | -1,500,000 | -1,400,000 | -1,750,000 | N/A |
| Common Stock Issued | 30,000 | 3,525,000 | 34,000 | 43,000 | 47,000 |
| Dividend Paid | -3,572,000 | -3,592,000 | -3,484,000 | -3,519,000 | -3,561,000 |
| Other Financing Activity | -308,000 | -182,000 | -67,000 | -34,000 | 2,000 |
| Financing Cash Flow | $-2,203,000 | $-1,765,000 | $-2,044,000 | $-2,936,000 | $-1,324,000 |
| Exchange Rate Effect | 12,000 | 5,000 | -38,000 | -66,000 | 21,000 |
| Beginning Cash Position | 5,223,000 | 4,671,000 | 3,172,000 | 4,924,000 | 6,051,000 |
| End Cash Position | 7,546,000 | 5,223,000 | 4,671,000 | 3,172,000 | 4,924,000 |
| Net Cash Flow | $2,323,000 | $552,000 | $1,499,000 | $-1,752,000 | $-1,127,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,799,000 | 2,969,000 | 2,618,000 | 3,578,000 | 4,145,000 |
| Capital Expenditure | -961,000 | -979,000 | -1,043,000 | -1,326,000 | -1,446,000 |
| Free Cash Flow | 3,838,000 | 1,990,000 | 1,575,000 | 2,252,000 | 2,699,000 |